Avidity End Period Cash Flow vs Sale Purchase Of Stock Analysis

RNA Stock

USD 30.11 1.01 3.25%

Avidity Biosciences financial indicator trend analysis is way more than just evaluating Avidity Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avidity Biosciences is a good investment. Please check the relationship between Avidity Biosciences End Period Cash Flow and its Sale Purchase Of Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.

End Period Cash Flow vs Sale Purchase Of Stock

End Period Cash Flow vs Sale Purchase Of Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avidity Biosciences End Period Cash Flow account and Sale Purchase Of Stock. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Avidity Biosciences' End Period Cash Flow and Sale Purchase Of Stock is -0.01. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Sale Purchase Of Stock in the same time period over historical financial statements of Avidity Biosciences, assuming nothing else is changed. The correlation between historical values of Avidity Biosciences' End Period Cash Flow and Sale Purchase Of Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Avidity Biosciences are associated (or correlated) with its Sale Purchase Of Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Sale Purchase Of Stock has no effect on the direction of End Period Cash Flow i.e., Avidity Biosciences' End Period Cash Flow and Sale Purchase Of Stock go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

End Period Cash Flow

Sale Purchase Of Stock

Most indicators from Avidity Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avidity Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.The current year's Selling General Administrative is expected to grow to about 56.9 M, whereas Issuance Of Capital Stock is forecasted to decline to about 221.3 M.

	2021	2022	2023	2024 (projected)
Research Development	101.2M	150.4M	191.0M	200.5M
Total Revenue	9.3M	9.2M	9.6M	6.4M

Research Development Total Revenue

Avidity Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total
Total Assets		0.84	0.92	0.99	-0.19	0.72	0.8	0.07	-0.69	0.94	0.33	-0.64	-0.8	0.93	-0.16	0.99	0.89	-0.81	-0.91	0.9	0.85	0.96	-0.85	0.86	-0.86	-0.28
Other Current Liab	0.84		0.73	0.87	-0.11	0.58	0.73	0.41	-0.58	0.69	0.17	-0.23	-0.64	0.83	0.13	0.8	0.87	-0.71	-0.72	0.87	0.65	0.88	-0.63	0.77	-0.63	-0.39
Total Current Liabilities	0.92	0.73		0.88	-0.24	0.67	0.52	-0.06	-0.61	0.98	0.4	-0.64	-0.67	0.93	0.03	0.93	0.8	-0.53	-0.99	0.8	0.68	0.82	-0.68	0.87	-0.69	-0.17
Total Stockholder Equity	0.99	0.87	0.88		-0.19	0.73	0.84	0.11	-0.66	0.9	0.19	-0.57	-0.76	0.92	-0.13	0.98	0.89	-0.83	-0.88	0.89	0.79	0.96	-0.8	0.8	-0.81	-0.42
Other Liab	-0.19	-0.11	-0.24	-0.19		0.1	0.09	0.64	-0.02	-0.3	0.02	0.53	-0.09	-0.24	-0.38	-0.31	-0.31	0.04	0.38	-0.3	0.0	-0.23	-0.01	-0.25	0.0	0.32
Accounts Payable	0.72	0.58	0.67	0.73	0.1		0.59	0.01	-0.63	0.7	0.25	-0.34	-0.68	0.56	-0.46	0.73	0.55	-0.59	-0.65	0.56	0.63	0.75	-0.66	0.64	-0.66	-0.23
Cash	0.8	0.73	0.52	0.84	0.09	0.59		0.37	-0.65	0.58	0.11	-0.34	-0.78	0.69	-0.38	0.75	0.75	-0.98	-0.51	0.77	0.83	0.84	-0.84	0.57	-0.83	-0.35
Other Assets	0.07	0.41	-0.06	0.11	0.64	0.01	0.37		-0.32	-0.15	-0.09	0.64	-0.31	0.15	0.01	-0.04	0.16	-0.29	0.17	0.17	0.19	0.12	-0.16	0.01	-0.14	0.0
Long Term Debt	-0.69	-0.58	-0.61	-0.66	-0.02	-0.63	-0.65	-0.32		-0.62	-0.42	0.23	0.96	-0.64	0.44	-0.69	-0.61	0.73	0.57	-0.63	-0.83	-0.73	0.84	-0.65	0.84	-0.07
Other Current Assets	0.94	0.69	0.98	0.9	-0.3	0.7	0.58	-0.15	-0.62		0.41	-0.75	-0.7	0.91	-0.07	0.96	0.82	-0.6	-0.99	0.82	0.74	0.86	-0.74	0.87	-0.76	-0.18
Total Liab	0.33	0.17	0.4	0.19	0.02	0.25	0.11	-0.09	-0.42	0.41		-0.47	-0.5	0.27	-0.24	0.29	0.33	-0.16	-0.41	0.34	0.6	0.36	-0.56	0.66	-0.57	0.76
Intangible Assets	-0.64	-0.23	-0.64	-0.57	0.53	-0.34	-0.34	0.64	0.23	-0.75	-0.47		0.36	-0.53	0.16	-0.67	-0.51	0.38	0.72	-0.52	-0.55	-0.56	0.57	-0.61	0.58	-0.01
Common Stock	-0.8	-0.64	-0.67	-0.76	-0.09	-0.68	-0.78	-0.31	0.96	-0.7	-0.5	0.36		-0.7	0.51	-0.77	-0.69	0.84	0.63	-0.71	-0.95	-0.83	0.95	-0.73	0.95	-0.08
Property Plant Equipment	0.93	0.83	0.93	0.92	-0.24	0.56	0.69	0.15	-0.64	0.91	0.27	-0.53	-0.7		0.14	0.92	0.93	-0.69	-0.91	0.93	0.72	0.87	-0.7	0.85	-0.71	-0.31
Short Long Term Debt Total	-0.16	0.13	0.03	-0.13	-0.38	-0.46	-0.38	0.01	0.44	-0.07	-0.24	0.16	0.51	0.14		-0.14	0.14	0.42	-0.07	0.1	-0.48	-0.19	0.53	0.0	0.53	-0.25
Net Tangible Assets	0.99	0.8	0.93	0.98	-0.31	0.73	0.75	-0.04	-0.69	0.96	0.29	-0.67	-0.77	0.92	-0.14		0.88	-0.78	-0.94	0.89	0.8	0.95	-0.81	0.85	-0.82	-0.34
Property Plant And Equipment Net	0.89	0.87	0.8	0.89	-0.31	0.55	0.75	0.16	-0.61	0.82	0.33	-0.51	-0.69	0.93	0.14	0.88		-0.76	-0.83	1.0	0.76	0.92	-0.73	0.9	-0.73	-0.31
Net Debt	-0.81	-0.71	-0.53	-0.83	0.04	-0.59	-0.98	-0.29	0.73	-0.6	-0.16	0.38	0.84	-0.69	0.42	-0.78	-0.76		0.53	-0.78	-0.87	-0.87	0.88	-0.6	0.88	0.32
Retained Earnings	-0.91	-0.72	-0.99	-0.88	0.38	-0.65	-0.51	0.17	0.57	-0.99	-0.41	0.72	0.63	-0.91	-0.07	-0.94	-0.83	0.53		-0.83	-0.67	-0.84	0.67	-0.89	0.68	0.21
Non Current Assets Total	0.9	0.87	0.8	0.89	-0.3	0.56	0.77	0.17	-0.63	0.82	0.34	-0.52	-0.71	0.93	0.1	0.89	1.0	-0.78	-0.83		0.78	0.93	-0.75	0.9	-0.75	-0.3
Non Currrent Assets Other	0.85	0.65	0.68	0.79	0.0	0.63	0.83	0.19	-0.83	0.74	0.6	-0.55	-0.95	0.72	-0.48	0.8	0.76	-0.87	-0.67	0.78		0.88	-1.0	0.81	-0.99	0.11
Cash And Short Term Investments	0.96	0.88	0.82	0.96	-0.23	0.75	0.84	0.12	-0.73	0.86	0.36	-0.56	-0.83	0.87	-0.19	0.95	0.92	-0.87	-0.84	0.93	0.88		-0.87	0.88	-0.87	-0.28
Common Stock Total Equity	-0.85	-0.63	-0.68	-0.8	-0.01	-0.66	-0.84	-0.16	0.84	-0.74	-0.56	0.57	0.95	-0.7	0.53	-0.81	-0.73	0.88	0.67	-0.75	-1.0	-0.87		-0.77	1.0	-0.08
Common Stock Shares Outstanding	0.86	0.77	0.87	0.8	-0.25	0.64	0.57	0.01	-0.65	0.87	0.66	-0.61	-0.73	0.85	0.0	0.85	0.9	-0.6	-0.89	0.9	0.81	0.88	-0.77		-0.78	0.04
Long Term Debt Total	-0.86	-0.63	-0.69	-0.81	0.0	-0.66	-0.83	-0.14	0.84	-0.76	-0.57	0.58	0.95	-0.71	0.53	-0.82	-0.73	0.88	0.68	-0.75	-0.99	-0.87	1.0	-0.78		-0.08
Non Current Liabilities Total	-0.28	-0.39	-0.17	-0.42	0.32	-0.23	-0.35	0.0	-0.07	-0.18	0.76	-0.01	-0.08	-0.31	-0.25	-0.34	-0.31	0.32	0.21	-0.3	0.11	-0.28	-0.08	0.04	-0.08

Click cells to compare fundamentals

Avidity Biosciences Account Relationship Matchups

Avidity Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	96.9M	333.9M	427.6M	638.8M	628.6M	660.0M
Other Current Liab	1.3M	10.9M	28.0M	60.9M	36.2M	20.9M
Total Current Liabilities	10.2M	14.6M	29.7M	51.9M	80.7M	84.7M
Total Stockholder Equity	(65.4M)	306.2M	381.4M	578.1M	500.8M	525.8M
Other Liab	15.1M	12.2M	6.5M	1.2M	1.1M	1.1M
Accounts Payable	2.3M	7.7M	2.8M	4.6M	8.8M	4.5M
Cash	94.6M	328.1M	405.5M	340.4M	185.1M	189.2M
Other Assets	600K	298K	850K	849K	1.0	0.95
Other Current Assets	1.1M	3.5M	5.6M	8.3M	14.9M	15.6M
Total Liab	162.3M	27.7M	46.2M	60.7M	127.8M	70.7M
Common Stock	1K	4K	5K	7K	8K	7.6K
Property Plant Equipment	631K	1.9M	15.6M	15.0M	17.3M	18.1M
Short Long Term Debt Total	4.9M	938K	10.0M	10.7M	9.9M	8.6M
Net Tangible Assets	(65.4M)	306.2M	381.4M	578.1M	664.8M	698.0M
Property Plant And Equipment Net	631K	1.5M	15.6M	15.0M	16.7M	9.2M
Net Debt	(89.6M)	(327.2M)	(395.6M)	(329.7M)	(175.2M)	(184.0M)
Retained Earnings	(22.2M)	(66.5M)	(184.5M)	(358.5M)	(570.8M)	(542.2M)
Non Current Assets Total	1.2M	2.2M	16.4M	15.9M	17.2M	9.9M
Non Currrent Assets Other	600K	501K	599K	598K	596K	537.5K
Cash And Short Term Investments	94.6M	328.1M	405.5M	610.7M	595.4M	373.5M
Common Stock Shares Outstanding	37.5M	21.7M	41.4M	52.2M	73.0M	45.2M
Liabilities And Stockholders Equity	96.9M	333.9M	427.6M	638.8M	628.6M	390.4M
Non Current Liabilities Total	152.0M	13.1M	16.5M	8.8M	47.1M	37.1M
Capital Lease Obligations	393K	938K	11.7M	7.6M	9.9M	5.6M
Other Stockholder Equity	(43.2M)	38.9M	566.2M	939.3M	1.1B	1.1B
Net Invested Capital	(60.8M)	306.2M	381.4M	578.1M	500.8M	307.1M
Property Plant And Equipment Gross	631K	1.5M	15.6M	15.0M	21.9M	23.0M
Total Current Assets	95.7M	331.7M	411.1M	622.9M	611.3M	380.6M
Accumulated Other Comprehensive Income	(134.7M)	(5K)	(187K)	(2.7M)	125K	131.3K
Capital Stock	0.0	4K	5K	7K	8K	7.6K
Net Working Capital	85.4M	317.1M	381.5M	571.0M	530.6M	345.5M
Short Term Debt	2.8M	7.7M	3.5M	6.2M	7.3M	5.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:

How To Invest In Avidity

Details

Is Avidity Stock a good investment?

Details

What is Avidity Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.88)

Revenue Per Share

0.103

Quarterly Revenue Growth

(0.17)

Return On Assets

(0.18)

Return On Equity

(0.28)

The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Avidity End Period Cash Flow vs Sale Purchase Of Stock Analysis

End Period Cash Flow vs Sale Purchase Of Stock

End Period Cash Flow vs Sale Purchase Of Stock Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Sale Purchase Of Stock

Avidity Biosciences fundamental ratios Correlations

Avidity Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Avidity Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets
Other Current Assets	+ 0.98	Total Current Liabilities
Net Tangible Assets	+ 0.98	Total Stockholder Equity

Common Stock Total Equity	- 1.0	Non Currrent Assets Other
Long Term Debt Total	- 0.99	Non Currrent Assets Other
Retained Earnings	- 0.99	Other Current Assets
Retained Earnings	- 0.99	Total Current Liabilities
Net Debt	- 0.98	Cash
Non Currrent Assets Other	- 0.95	Common Stock